A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)
Clinical trial NCT05637255 · COMPLETED
Trial details
- NCT number
- NCT05637255
- Sponsor
- Sylentis, S.A.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-22
- Primary completion
- 2024-12-19
- Enrollment
- 99
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.